Interactions between galectin-3 and cardiovascular risk in patients with chronic lymphocytic leukemia in remission: results of 3-year prospective study

Abstract Purpose – to evaluate interactions between the value of circulating galectin-3 and cardiovascular risk in patients with chronic lymphocytic leukemia in remission. Materials and methods. One hundred fifty seven out subjects with chronic lymphocytic leukemia in full or partial remission w... Ausführliche Beschreibung

1. Person: B. B. Samura verfasserin
Quelle: In Aktualʹnì Pitannâ Farmacevtičnoï ì Medičnoï Nauki ta Praktiki (01.10.2018)
Weitere Artikel
Format: Online-Artikel
Sprache: English
Russian
Ukrainian
Veröffentlicht: 2018
Beschreibung: Online-Ressource
Online Zugang: Online
Online
Online
Online
Online
Volltext
Tags: Hinzufügen
Keine Tags. Fügen Sie den ersten Tag hinzu!
  Creative Commons License Source: Directory of Open Access Journals (DOAJ).
LEADER 02940nma a2200289 c 4500
001 DOAJ034951334
003 DE-601
005 20190330134135.0
007 cr uuu---uuuuu
008 181102s2018 000 0 eng d
024 7 |a 10.14739/2409-2932.2018.3.145251  |2 doi 
035 |a (DE-599)DOAJf1970e8514b74580b0d64b7344390b94 
040 |b ger  |c GBVCP 
041 0 |a eng  |a rus  |a ukr 
100 0 |a B. B. Samura  |e verfasserin  |4 aut 
245 1 0 |a Interactions between galectin-3 and cardiovascular risk in patients with chronic lymphocytic leukemia in remission: results of 3-year prospective study  |h Elektronische Ressource 
300 |a Online-Ressource 
520 |a Abstract Purpose – to evaluate interactions between the value of circulating galectin-3 and cardiovascular risk in patients with chronic lymphocytic leukemia in remission. Materials and methods. One hundred fifty seven out subjects with chronic lymphocytic leukemia in full or partial remission were enrolled in the study. Observation period was up to 12 months. Blood samples for biomarkers measurements were collected at the visit of inclusion into the study. ELISA method for measurements of circulating level of galectin-3 was used. Cardiovascular events were evaluated for 3 year observation period. Results. Two hundred seventy cumulative clinical events occurred in 68 patients (43.3 %) within the follow-up, with their distribution being as follows: 12 deaths for cardiovascular reasons, 17 life-threatening arrhythmias, 36 cardiac ischemic events, 9 strokes, 38 decompensated chronic heart failures and 58 hospital admissions for cardiovascular reasons. Mean levels of galectin-3 in free-events subject cohort and subjects cohort with cardiovascular events were 5.22 ± 3.06 ng/ml and 12.64 ± 5.24 ng/ml (Р < 0.0001). In patients after antitumor treatment with anthracyclines mean levels of galectin-3 were higher in comparing with patients after antitumor treatment without anthracyclines (Р = 0.0014). There were no differences in the value of galectin-3 in depend on gender, age, cumulative dose of anthracyclines, arterial hypertension, hyperlipidemia, diabetes mellitus, body mass index, smoking. Conclusions. Among patients with chronic lymphocytic leukemia in remission increased circulating galectin-3 associates with presence of anthracyclines in antitumor treatment and increased cumulative cardiovascular events within 3 year observation period. 
773 0 8 |i In  |t Aktualʹnì Pitannâ Farmacevtičnoï ì Medičnoï Nauki ta Praktiki  |g  (01.10.2018)  |w (DE-601)DOAJ000032042  |x 2306-8094 
856 4 0 |u http://dx.doi.org/10.14739/2409-2932.2018.3.145251 
856 4 0 |y DOAJ  |u https://doaj.org/article/f1970e8514b74580b0d64b7344390b94 
856 4 0 |u http://pharmed.zsmu.edu.ua/article/view/145251/143608 
856 4 0 |u https://doaj.org/toc/2306-8094 
856 4 0 |u https://doaj.org/toc/2409-2932 
912 |a GBV_DOAJ 
951 |a AR 
952 |j 2018  |b 01  |c 10 

Ähnliche Einträge

Keine ähnlichen Titel gefunden

Privacy Notice Ask a Librarian New Acquisitions